In which countries is Enasidenib approved?

Enasidenib is the first targeted drug approved to treat IDH2-mutant acute myeloid leukemia (AML). On August 1, 2017, the U.S. Food and Drug Administration (FDA) approved its marketing for the treatment of adult patients with relapsed or refractory acute myeloid leukemia who carry specific IDH2 gene mutations. This approval is landmark because it marks a new stage in precision treatment of AML. Different from traditional chemotherapy regimens, ensidipine uses companion diagnostics, namely real-time IDH2 gene testing, to screen out suitable patient groups to ensure that the drug works accurately and efficiently.

It is worth noting that the approval of ensidipine was accompanied by supporting diagnostic tools, which was also a major trend in the FDA's approval of targeted drugs at that time, that is, the "bundled" marketing of drugs and companion diagnostic reagents. The significance of this is to quickly identify the target population, avoid blind use of drugs, and improve the pertinence and cost-effectiveness of treatment.

Currently, the listing of ensidipine is mainly limited to the United States. The European Medicines Agency (EMA) has not yet officially approved the drug, and other countries such as China and Japan have not yet included it in routine clinical use. This means that in most regions, patients will still need to go through clinical trials or international drug introduction channels to obtain the drug. In the future, with the popularization of AML molecular typing diagnosis and the release of more research results on the efficacy and safety of ensidipine, its global registration and marketing may gradually advance.

In general, ensidipine, as an IDH2-targeted inhibitor, was not only the first to be approved in the United States, it changed the treatment landscape of AML, but also provided a reference model for the development and approval of more molecular target drugs in the future. As time goes by, more and more countries and regions may gradually introduce this drug, allowing more patients to benefit from it.

Reference materials:https://www.idhifa.com/